194 related articles for article (PubMed ID: 32003597)
21. Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease.
Kuwahara M; Mandai S; Kasagi Y; Kusaka K; Tanaka T; Shikuma S; Akita W
Clin Exp Nephrol; 2015 Aug; 19(4):598-605. PubMed ID: 25183365
[TBL] [Abstract][Full Text] [Related]
22. Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilisation in Treatment of Anaemia in Patients with Chronic Kidney Disease.
Hayashi T; Nagamatsu T; Matsushita A; Mizuno T; Nishibe S; Noguchi A; Kato R; Toda T; Tanaka J; Takahashi H; Hayashi H; Yuzawa Y; Yamada S
Biol Pharm Bull; 2015; 38(5):740-5. PubMed ID: 25740003
[TBL] [Abstract][Full Text] [Related]
23. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
Am J Nephrol; 2021; 52(9):702-713. PubMed ID: 34628408
[TBL] [Abstract][Full Text] [Related]
24. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
25. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
26. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
Malyszko J; Glowinska I; Mysliwiec M
Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
[TBL] [Abstract][Full Text] [Related]
27. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study.
Tanaka S; Kitamura H; Tsuruya K; Kitazono T; Nakano T;
Clin Exp Nephrol; 2022 Sep; 26(9):867-879. PubMed ID: 35507237
[TBL] [Abstract][Full Text] [Related]
28. Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Patients with Non-Dialysis-Dependent Chronic Kidney Disease (RADIANCE-CKD Study).
Mase K; Yamagata K; Yamamoto H; Tsuruya K; Hase H; Nishi S; Nangaku M; Wada T; Hayashi T; Uemura Y; Hirakata H
Am J Nephrol; 2023; 54(11-12):471-478. PubMed ID: 37793365
[TBL] [Abstract][Full Text] [Related]
29. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
Weir MR
Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
[TBL] [Abstract][Full Text] [Related]
30. Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials.
Tsuruya K; Uemura Y; Hirakata H; Kitazono T; Tsubakihara Y; Suzuki M; Ohashi Y
Nephrology (Carlton); 2017 Oct; 22(10):769-775. PubMed ID: 27312361
[TBL] [Abstract][Full Text] [Related]
31. Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.
Thamer M; Zhang Y; Kshirsagar O; Cotter DJ; Kaufman JS
Am J Kidney Dis; 2014 Nov; 64(5):706-13. PubMed ID: 25011692
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and related factors of the absence of anemia among Chinese chronic hemodialysis patients: a multicenter cross-sectional study.
Wan Q; He Y; Zhang W; Wu Q; Xiong Z
Int Urol Nephrol; 2014 Aug; 46(8):1651-4. PubMed ID: 24114285
[TBL] [Abstract][Full Text] [Related]
33. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach.
Thavarajah S; Choi MJ
Am J Kidney Dis; 2019 Nov; 74(5):667-674. PubMed ID: 31395400
[TBL] [Abstract][Full Text] [Related]
34. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
35. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
36. Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.
Kimachi M; Fukuma S; Yamazaki S; Yamamoto Y; Akizawa T; Akiba T; Saito A; Fukuhara S
Nephron; 2015; 131(2):123-30. PubMed ID: 26344924
[TBL] [Abstract][Full Text] [Related]
37. A retrospective database analysis of erythropoiesis-stimulating agent treatment patterns and associated healthcare resource use in patients with non-dialysis-dependent chronic kidney disease-related anaemia in Japan.
Mishina S; Waratani M; Onozawa S; Okumura H; Ito Y; Yasuda Y
Nephrology (Carlton); 2023 Aug; 28(8):446-455. PubMed ID: 37161826
[TBL] [Abstract][Full Text] [Related]
38. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.
Hayashi T; Maruyama S; Nangaku M; Narita I; Hirakata H; Tanabe K; Morita S; Tsubakihara Y; Imai E; Akizawa T;
Clin J Am Soc Nephrol; 2020 May; 15(5):608-615. PubMed ID: 32245781
[TBL] [Abstract][Full Text] [Related]
39. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
[TBL] [Abstract][Full Text] [Related]
40. [Adherence to treatment with erythropoiesis stimulating agents].
Pérez Díez C; Navarro Aznárez H; Lou Arnal LM
An Sist Sanit Navar; 2020 Apr; 43(1):81-85. PubMed ID: 32242547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
